953400-68-5
Chemical Structure
Lebrikizumab
Synonym(s): TNX-650; MILR1444A; RG3637
- CAS No.: 953400-68-5
- Formula:N/A
- Molecular Weight:(145.318 kDa)
IUPAC Name: 1-(2-(ethoxy-d5)ethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzo[d]imidazole
SMILES: [Lebrikizumab]
Biological Activity: Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lebrikizumab | 99.90% | Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jonathan Corren, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22;365(12):1088-98. [Content Brief]
- [2]. Loh TY, et al. Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis. J Asthma Allergy. 2020 Feb 11;13:109-114. [Content Brief]
- [3]. Miron Y, et al. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2022 Sep;150(3):690-700. [Content Brief]
